Avalo Therapeutics Files 8-K for 'Other Event' on Jan 30
Ticker: AVTX · Form: 8-K · Filed: Jan 31, 2024 · CIK: 1534120
| Field | Detail |
|---|---|
| Company | Avalo Therapeutics, INC. (AVTX) |
| Form Type | 8-K |
| Filed Date | Jan 31, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $1.00 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative, compliance, 8-K
TL;DR
**Avalo Therapeutics filed a routine 8-K, no major news.**
AI Summary
Avalo Therapeutics, Inc. filed an 8-K on January 31, 2024, reporting an "Other Event" that occurred on January 30, 2024. This filing is a routine administrative update, confirming the company's current status and registration details with the SEC, including its trading symbol AVTX on the Nasdaq Capital Market. For investors, this filing primarily serves as a confirmation of the company's ongoing compliance and operational status, indicating no immediate material changes that would significantly impact stock value.
Why It Matters
This filing is a standard administrative update, confirming Avalo Therapeutics' continued compliance with SEC reporting requirements and its listing on the Nasdaq Capital Market.
Risk Assessment
Risk Level: low — This filing is purely administrative and does not disclose any new financial, operational, or strategic risks.
Analyst Insight
A smart investor would recognize this as a routine compliance filing with no new material information, suggesting no immediate action is warranted based solely on this 8-K.
Key Players & Entities
- Avalo Therapeutics, Inc. (company) — registrant filing the 8-K
- Nasdaq Capital Market (company) — exchange where Avalo Therapeutics' common stock is registered
- AVTX (company) — trading symbol for Avalo Therapeutics' common stock
- January 30, 2024 (date) — date of earliest event reported
- January 31, 2024 (date) — date the 8-K was filed
FAQ
What was the specific 'Other Event' reported by Avalo Therapeutics, Inc. on January 30, 2024?
The filing indicates an 'Other Event' occurred on January 30, 2024, but the document itself does not provide specific details about the nature of this event beyond its classification as 'Other Events' under Item Information.
On which stock exchange is Avalo Therapeutics, Inc.'s common stock traded?
Avalo Therapeutics, Inc.'s Common Stock, $0.001 Par Value, is registered on the Nasdaq Capital Market, as stated in the 'Securities registered pursuant to Section 12(b) of the Act' section.
What is the trading symbol for Avalo Therapeutics, Inc.?
The trading symbol for Avalo Therapeutics, Inc.'s common stock is AVTX, as listed under 'Trading Symbol(s)' in the filing.
What is the business address of Avalo Therapeutics, Inc.?
The business address of Avalo Therapeutics, Inc. is 540 Gaither Road, Suite 400, Rockville, Maryland 20850, with a business phone number of (410) 522-8707.
Is Avalo Therapeutics, Inc. classified as an 'emerging growth company' according to this filing?
No, the filing indicates with a checkbox that Avalo Therapeutics, Inc. is not an 'emerging growth company' as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Filing Stats: 632 words · 3 min read · ~2 pages · Grade level 13.3 · Accepted 2024-01-31 16:01:27
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 Par Value AVTX Nasdaq Capital Market
- $1.00 — mmon stock had closed below the minimum $1.00 per share requirement for continued inc
Filing Documents
- avtx-20240130.htm (8-K) — 24KB
- 0001628280-24-002715.txt ( ) — 145KB
- avtx-20240130.xsd (EX-101.SCH) — 2KB
- avtx-20240130_lab.xml (EX-101.LAB) — 24KB
- avtx-20240130_pre.xml (EX-101.PRE) — 12KB
- avtx-20240130_htm.xml (XML) — 3KB
01 Other Information
Item 8.01 Other Information. As previously reported, on August 8, 2023, Nasdaq Stock Market LLC ("Nasdaq") notified Avalo Therapeutics, Inc. (the "Company") that for the last 30 consecutive business days, the bid price for the Company's common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"). The Company affected a reverse stock split on December 28, 2023, which has allowed its common stock to trade above $1.00 since December 29, 2023. On January 30, 2024, the Company received written notification from Nasdaq confirming that the Company had regained compliance with the Bid Price Rule. Nasdaq also notified the Company that it is subject to a mandatory panel monitor for a period of one year from January 30, 2024. If, within the one-year monitoring period, Nasdaq finds the Company again out of compliance with the Bid Price Rule, then notwithstanding Nasdaq Rule 5810(c)(2), the Company will not be permitted to provide Nasdaq with a plan of compliance with respect to that deficiency and Nasdaq will not be permitted to grant additional time for the Company to regain compliance with respect to that deficiency, nor will the Company be afforded an applicable cure or compliance period pursuant to Nasdaq Rule 5810(c)(3). Instead, Nasdaq will issue a Delist Determination Letter and the Company will have an opportunity to request a new hearing with the initial Nasdaq panel assigned to the Company for its recent noncompliance or newly convened hearings panel if the initial panel is unavailable. The Company will have the opportunity to respond to the hearings panel as provided by Nasdaq Rule 5815(d)(4)(C). If the Company fails to satisfy the Nasdaq panel, its securities would be delisted from Nasdaq. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on i